Satoh T, Fujita K I, Munakata H, Itoh S, Nakamura K, Kamataki T, Itoh S, Yoshizawa I
Hokkaido College of Pharmacy, Otaru, Hokkaido, 047-0264, Japan.
Anal Biochem. 2000 Nov 15;286(2):179-86. doi: 10.1006/abio.1999.4775.
To establish a prediction system for drug-induced gynecomastia in clinical fields, a model reaction system was developed to explain numerically this side effect. The principle is based on the assumption that 50% inhibition concentration (IC(50)) of drugs on the in vitro metabolism of estradiol (E2) to its major product 2-hydroxyestradiol (2-OH-E2) can be regarded as the index for achieving this purpose. By using human cytochrome P450s coexpressed with human NADPH-cytochrome P450 reductase in Escherichia coli as the enzyme, the reaction was examined. Among the nine enzymes (CYP1A1, 1A2, 2A6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4) tested, CYP3A4 having a V(max)/K(m) (ml/min/nmol P450) value of 0.32 for production of 2-OH-E2 was shown to be the most suitable enzyme as the reagent. The inhibitory effects of ketoconazole, cyclosporin A, and cimetidine toward the 2-hydroxylation of E2 catalyzed by CYP3A4 were obtained, and their IC(50) values were 7 nM, 64 nM, and 290 microM, respectively. The present results suggest that IC(50) values thus obtained can be substituted as the prediction index for gynecomastia induced by drugs, considering the patients' individual information.
为在临床领域建立药物性乳腺增生的预测系统,开发了一个模型反应系统以对这种副作用进行数值解释。该原理基于这样的假设,即药物对雌二醇(E2)体外代谢为其主要产物2-羟基雌二醇(2-OH-E2)的50%抑制浓度(IC(50))可被视为实现此目的的指标。以在大肠杆菌中与人NADPH-细胞色素P450还原酶共表达的人细胞色素P450作为酶,对该反应进行了研究。在所测试的九种酶(CYP1A1、1A2、2A6、2C8、2C9、2C19、2D6、2E1和3A4)中,对于生成2-OH-E2的V(max)/K(m)(ml/分钟/纳摩尔P450)值为0.32的CYP3A4被证明是最适合作为试剂的酶。获得了酮康唑、环孢素A和西咪替丁对CYP3A4催化的E2的2-羟基化反应的抑制作用,其IC(50)值分别为7 nM、64 nM和290 microM。目前的结果表明,考虑到患者的个体信息,由此获得的IC(50)值可替代作为药物诱导乳腺增生的预测指标。